{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:12:14Z","timestamp":1789157534177,"version":"build-2803163510"},"reference-count":30,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:p>Aim: To determine the prevalence of multidrug-resistant rectal colonization and bloodstream infection in children with high-risk leukemia receiving levofloxacin prophylaxis, to assess changes in fluoroquinolone susceptibility across chemotherapy cycles, and to examine concordance between rectal surveillance cultures and bloodstream infection.\nMaterials and Methods: This retrospective cohort included 82 children aged 18 years or younger with acute myeloid leukemia or relapsed acute lymphoblastic leukemia treated with intensive chemotherapy and levofloxacin prophylaxis. Rectal swabs were obtained during febrile neutropenia when available, blood cultures were obtained for all febrile neutropenia episodes, and empirical meropenem was modified according to culture results. Multidrug resistance was classified according to published consensus criteria.\nResults: Median age was 10 years, 67.1% were male, and 82.9% had acute myeloid leukemia. Febrile neutropenia occurred in 89.3% of chemotherapy cycles. Rectal colonization was dominated by multidrug-resistant Klebsiella species and multidrug-resistant Escherichia coli. Bloodstream infection was dominated by multidrug-resistant Klebsiella pneumoniae and multidrug-resistant Escherichia coli. Fluoroquinolone susceptibility was low in both rectal isolates (16%) and bloodstream isolates (11.8%) and decreased further across successive cycles. Mortality was associated with multidrug-resistant Klebsiella pneumoniae bloodstream infection and fluoroquinolone resistance in bloodstream isolates.\nConclusions: In this resistance setting, routine levofloxacin prophylaxis appears to offer limited benefit and may promote rapid expansion of resistant gramnegative flora. Rectal surveillance together with culture-directed therapy may better support antimicrobial stewardship and early risk-adapted treatment.<\/jats:p>","DOI":"10.36740\/merkur202604111","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:54:56Z","timestamp":1789156496000},"page":"449","source":"Crossref","is-referenced-by-count":0,"title":["Impact of multidrug resistant bloodstream infection burden, prophylactic levofloxacin and rectal swab practice on children with high-risk leukemias"],"prefix":"10.36740","volume":"54","author":[{"given":"Muhammad","family":"Alsabagh","sequence":"first","affiliation":[{"name":"PEDIATRIC ONCOLOGY DEPARTMENT, NATIONAL CANCER INSTITUTE, CAIRO UNIVERSITY, CAIRO, EGYPT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moatasem","family":"Elayadi","sequence":"additional","affiliation":[{"name":"PEDIATRIC ONCOLOGY DEPARTMENT, NATIONAL CANCER INSTITUTE, CAIRO UNIVERSITY, CAIRO, EGYPT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Kadry","sequence":"additional","affiliation":[{"name":"CLINICAL PATHOLOGY DEPARTMENT, NATIONAL CANCER INSTITUTE, CAIRO UNIVERSITY, CAIRO, EGYPT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fawzy","sequence":"additional","affiliation":[{"name":"PEDIATRIC ONCOLOGY DEPARTMENT, NATIONAL CANCER INSTITUTE, CAIRO UNIVERSITY, CAIRO, EGYPT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. doi:10.1056\/NEJMra052603.","DOI":"10.1056\/NEJMra052603"},{"key":"ref1","unstructured":"2. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014. https:\/\/www.who.int\/publications\/i\/item\/9789241564748 (Access: January 2026)."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28-S36. doi:10.1093\/infdis\/jiw282.","DOI":"10.1093\/infdis\/jiw282"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450-470. doi:10.1128\/CMR.05041-11.","DOI":"10.1128\/CMR.05041-11"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093\/cid\/cir073.","DOI":"10.1093\/cid\/cir073"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;(1):CD004386. doi:10.1002\/14651858.CD004386.pub3.","DOI":"10.1002\/14651858.CD004386.pub3"},{"key":"ref6","unstructured":"7. Simon A, Furtwangler R, Graf N, et al. Surveillance of bloodstream infections in pediatric cancer centres: what have we learned and how do we move on? GMS Hyg Infect Control. 2016;11:Doc11. doi:10.3205\/dgkh000271."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Taur Y, Pamer EG. The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis. 2013;26(4):332-337. doi:10.1097\/QCO.0b013e3283630dd3.","DOI":"10.1097\/QCO.0b013e3283630dd3"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Jara JH, Huynh J, Sieswerda E, et al. Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study. Antimicrob Resist Infect Control. 2022;11:147. doi:10.1186\/s13756-022-01198-5.","DOI":"10.1186\/s13756-022-01198-5"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Alayed T, Mobarak O, Azem A, et al. Outcomes of pediatric rapid response teams at a hematology\/oncology center in Riyadh, Saudi Arabia. Int J Pediatr Adolesc Med. 2025;12:12-19. doi:10.4103\/ijpam.ijpam_156_24.","DOI":"10.4103\/ijpam.ijpam_156_24"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Agulnik A. Management of septic shock in children with cancer: common challenges and research priorities. J Pediatr (Rio J). 2023; 99(Suppl 1):S13-S20. doi:10.1016\/j.jped.2023.01.001.","DOI":"10.1016\/j.jped.2023.01.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Azevedo RT, Araujo OR, Petrilli AS, Silva DCB. Children with malignancies and septic shock: an attempt to understand the risk factors. J Pediatr (Rio J). 2023;99(4):350-357. doi:10.1016\/j.jped.2022.09.003.","DOI":"10.1016\/j.jped.2022.09.003"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Aljabari S, Balch A, Larsen GY, Fluchel M, Workman JK. Severe sepsis-associated morbidity and mortality among critically ill children with cancer. J Pediatr Intensive Care. 2019; 8(3):122-129. doi:10.1055\/s-0038-1676658.","DOI":"10.1055\/s-0038-1676658"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Mukkada S, Melgar M, Bullington C, et al. High morbidity and mortality associated with primary bloodstream infections among pediatric patients with cancer at a Guatemalan tertiary referral hospital. Front Public Health. 2022;10:1007769. doi:10.3389\/fpubh.2022.1007769.","DOI":"10.3389\/fpubh.2022.1007769"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Hassouneh D, Zatarah R, AbuSara A, et al. Microbiological profiles and resistance patterns in pediatrics with cancer: an 8-year study at a comprehensive cancer center in Jordan. Cancer Rep (Hoboken). 2025;8:e70132. doi:10.1002\/cnr2.70132.","DOI":"10.1002\/cnr2.70132"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Madney Y, Aboubakr S, Khedr R, et al. Carbapenem-resistant Enterobacteriaceae among children with cancer: predictors of mortality and treatment outcome. Antibiotics (Basel). 2023;12(2):405. doi:10.3390\/antibiotics12020405.","DOI":"10.3390\/antibiotics12020405"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. S\u0119kowska A, Czy\u017cewski K, Jaremek K, et al. Infections with Klebsiella pneumoniae in children undergoing anticancer therapy or hematopoietic cell transplantation: a multicenter nationwide study. J Clin Med. 2024;13(14):4078. doi:10.3390\/jcm13144078.","DOI":"10.3390\/jcm13144078"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Khedr R, Abdelwahab N, Kadry D, Hamdy R. Gut colonization with multidrug-resistant organisms and its impact on bloodstream infection in children with haematological malignancies: a prospective observational study. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.2442. doi:10.1093\/ofid\/ofae631.2442.","DOI":"10.1093\/ofid\/ofae631.2442"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Alzu\u2019bi D, Obeidat H, Ghabashineh D, et al. The microbial spectrum and antimicrobial resistance pattern in pediatric cancer patients with febrile neutropenia at King Abdullah University Hospital, Jordan. Egypt Pediatr Assoc Gaz. 2024;72:49. doi:10.1186\/s43054-024-00249-3.","DOI":"10.1186\/s43054-024-00249-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Gallardo-Pizarro A, Lopera C, Peyrony O, et al. Rectal colonization by multidrug-resistant gram-negative bacteria and subsequent bacteraemia in haematological patients. Clin Microbiol Infect. 2025;44(3):567-576. doi:10.1016\/j.cmi.2025.05.033.","DOI":"10.1016\/j.cmi.2025.05.033"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Quintero AM, Cruz DA, Klamer BG, Ardura MI, Oyeniran SJ. Emerging resistance trends in viridans group streptococci bloodstream infections among immunocompromised children receiving levofloxacin prophylaxis. J Pediatric Infect Dis Soc. 2023;12(7):381-391. doi:10.1093\/jpids\/piad041.","DOI":"10.1093\/jpids\/piad041"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Caro J, Madero-Marroquin R, Zubizarreta N, et al. Impact of fluoroquinolone prophylaxis on neutropenic fever, infections, and antimicrobial resistance in newly diagnosed AML patients. Clin Lymphoma Myeloma Leuk. 2022;22(12):903-911. doi:10.1016\/j.clml.2022.08.001.","DOI":"10.1016\/j.clml.2022.08.001"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Ragab I, Gawad ANA, Anwar MA, Soliman AAAEH. Rectal colonization study and its impact on bloodstream infection in hospitalized pediatric oncology patients. QJM. 2024;117(Suppl 2):hcae175.729. doi:10.1093\/qjmed\/hcae175.729.","DOI":"10.1093\/qjmed\/hcae175.729"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Meng H, Yang J, Niu M, Zhu H, Zhou Y, Lu J. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study. Int J Antimicrob Agents. 2023;62(6):106933. doi:10.1016\/j.ijantimicag.2023.106933.","DOI":"10.1016\/j.ijantimicag.2023.106933"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi:10.1111\/j.1469-0691.2011.03570.x.","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Rashidi A, Weisdorf DJ. Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Transl Res. 2020;220:167-181. doi:10.1016\/j.trsl.2020.03.011.","DOI":"10.1016\/j.trsl.2020.03.011"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Nanayakkara AK, Boucher HW, Fowler VG Jr, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: escalating challenges and paths forward. CA Cancer J Clin. 2021;71(6):488-504. doi:10.3322\/caac.21697.","DOI":"10.3322\/caac.21697"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation. JAMA. 2018;320(10):995-1004. doi:10.1001\/jama.2018.12512.","DOI":"10.1001\/jama.2018.12512"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Vasileiadi E, Lloyd KM, Fisher BT, Hanisch B. Fluoroquinolone prophylaxis in children with cancer: a pro\/con discussion. J Pediatric Infect Dis Soc. 2024;13(9):486-492. doi:10.1093\/jpids\/piae077.","DOI":"10.1093\/jpids\/piae077"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20-37. doi:10.1016\/j.jinf.2017.10.009.","DOI":"10.1016\/j.jinf.2017.10.009"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:55:09Z","timestamp":1789156509000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2026i4net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202604111","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}